Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Enterprise Value: 2012-2025

Historic Enterprise Value for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to $1.4 billion.

  • Agios Pharmaceuticals' Enterprise Value fell 9.43% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 219.27%. This contributed to the annual value of $980.3 million for FY2024, which is 109.57% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Enterprise Value stood at $1.4 billion, which was up 39.70% from $987.3 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Enterprise Value ranged from a high of $2.2 billion in Q2 2021 and a low of $395.4 million during Q2 2022.
  • Moreover, its 3-year median value for Enterprise Value was $980.3 million (2024), whereas its average is $1.0 billion.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Enterprise Value crashed by 81.87% in 2022, and later spiked by 120.43% in 2023.
  • Agios Pharmaceuticals' Enterprise Value (Quarterly) stood at $765.1 million in 2021, then dropped by 0.70% to $759.7 million in 2022, then plummeted by 38.43% to $467.8 million in 2023, then skyrocketed by 109.57% to $980.3 million in 2024, then decreased by 9.43% to $1.4 billion in 2025.
  • Its Enterprise Value was $1.4 billion in Q3 2025, compared to $987.3 million in Q2 2025 and $785.4 million in Q1 2025.